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Intratympanic Gentamicin 
Treatment for Ménière’s Disease
Yongchuan Chai and Hongzhe Li
Abstract
Ménière’s disease (MD) is an inner-ear disease mostly characterized by frequent 
spontaneous vertigo and fluctuating sensorineural hearing loss. The main purpose 
of treatment for MD is to reduce or control the vertigo while maximizing the 
preservation of hearing. Among the various treatments, one that is effective for 
refractory MD, intratympanic gentamicin (ITG), relies on its ototoxic property to 
effectively control the vertigo symptoms of most patients. ITG treatment has rela-
tively few side effects compared with surgically destructive treatments, but it also 
carries a nonnegligible risk of sensorineural hearing loss. So far, there is no consen-
sus on the dosage and treatment duration of ITG. Most researchers recommend that 
intratympanic injection of gentamicin is more suitable for patients with unilateral 
onset and impaired hearing function, who are younger than 65 years old, as well as 
with frequent and severe vertigo attacks, and ineffective prior conservative treat-
ment. Before an ITG treatment, patients should be adequately informed about the 
risk of hearing loss, and in order to reduce the risk of deafness, low drug dose and 
long intervals between injections are recommended. In short, to administer an ITG 
injection, multiple factors should be comprehensively considered including patient 
selection, pharmacological mechanism, drug dose, the interval of administration, 
complications, indications, and contraindications.
Keywords: intratympanic, gentamicin, Ménière’s disease, management, 
aminoglycosides, vertigo, vestibulotoxicity, ototoxicity
1. Introduction
Ménière’s disease (MD), also called idiopathic endolymphatic hydrops, is one 
of the most common causes of dizziness originating in the inner ear. The typical 
clinical manifestations are frequent spontaneous vertigo, fluctuating sensorineural 
hearing loss, tinnitus, and/or aural fullness. Vertigo is typically the most debilitat-
ing symptom, and control of vertiginous episodes is the primary goal of therapeutic 
interventions for most patients.
There are numerous available therapeutic options for MD including conservative 
treatments with dietary modifications, oral medication, procedural treatments with 
intratympanic therapies, and surgical treatments. A failure of conservative therapy 
often introduces the need for a more aggressive therapy on the treatment algorithm.
Surgical intervention or intratympanic aminoglycosides can be used in patients 
with intractable vertigo, which, ideally, should control the vertigo while preserv-
ing the hearing level and balance. The side effects of aminoglycosides are well-
know. The risks of vestibular and cochlear toxicity are mainly related to types of 
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aminoglycosides, route of administration, duration of the therapy, total or cumula-
tive dose, individual susceptibility, renal function, patient’s age, etc.
In 1948, Fowler [1] first used systemic streptomycin to treat vertigo attacks 
in patients with intractable MD. The results showed that vertigo attacks could be 
well controlled, but treatment carried the risks of bilateral vestibulopathy, neph-
rotoxicity, and unpredictable results. In 1957, Schuknekt [2] may have been the 
first to use intratympanic streptomycin to alleviate vertigo attacks in patients with 
unilateral intractable MD, and it was firstly named “chemical labyrinthectomy”. 
Intratympanic gentamicin (ITG) for the treatment of severe vertigo was reported 
by Lange [3]. The initial approach was complete vestibular ablation to control the 
vertigo. However, with this approach, the hearing was at a greater risk. Over the 
past decades, the pharmacological mechanisms of aminoglycosides have been 
progressively studied in depth and clinical trials have been extensively developed.
At present, intratympanic injection of gentamicin is probably the most effective 
non-surgical treatment to eradicate vertigo in MD and is gradually gaining popular-
ity in the worldwide. Compared with the treatment regimen decades ago, several 
modifications for ITG treatment have emerged regarding the concentration of the 
gentamicin solution, the frequency of injections, and the method of delivery. In 
this chapter, the history, background, and progression of ITG treatment for MD 
are discussed, as well as the basic science, therapeutic method, treatment efficacy, 
indications, contraindications, and complications.
2. History of intratympanic gentamicin
Aminoglycosides are highly potent, broad-spectrum antibiotics and are widely 
used by various routes of injection to treat serious infections caused by Gram-negative 
bacteria (e.g., Pseudomonas aeruginosa, Proteus species, Escherichia coli, Klebsiella-
Enterobacter-Serratia species, and Citrobacter species), and are sometimes used as an 
adjuvant treatment for infections caused by Gram-positive bacteria (e.g., Staphylococcus 
species). The basic chemical structure required for both potency and the spectrum of 
antimicrobial activity of aminoglycosides is that of one, or several, aminated sugars 
joined in glycosidic linkages to a dibasic cyclitol. Aminoglycosides act primarily by 
impairing bacterial protein synthesis through binding to prokaryotic ribosomes [4].
Streptomycin, which was discovered in 1944, is the first aminoglycoside antibi-
otic in human history and was thereafter marked by the successive introduction of a 
series of milestone compounds (kanamycin discovered in 1957, gentamicin in 1963, 
and neomycin in 1970s) which definitively established the usefulness of this class of 
antibiotics for the treatment of Gram-negative bacillary infections. From the 1960s 
to 1970s, aminoglycosides were widely used, but due to their serious ototoxicity 
and nephrotoxicity, their systemic application was limited, and they were gradu-
ally fading out of the ranks of first-line drugs. At the beginning, the most common 
side effect of streptomycin used by intravenous injection was temporary imbal-
ance without vertigo or nystagmus. Higher systemic doses increased the chance of 
permanent imbalance and, occasionally, deafness. These early observations led to 
animal and cadaver studies which confirmed the vestibulotoxic and cochleotoxic 
effects of high-dose streptomycin.
Based on its vestibulotoxicity, streptomycin foremost unveiled its potential in 
the treatment of vestibular diseases. In 1948, about 4 years after streptomycin was 
discovered, Fowler [1] first used systemic streptomycin to treat vertigo attacks in 
patients with intractable MD which was refractory to traditional medical treatment. 
He and others used between 2 and 4 g of intramuscular streptomycin per day in 
patients with unilateral or bilateral MD, typically until onset of severe imbalance, 
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and reported that vertigo attacks could be well controlled without loss of hearing. 
Often, and especially with higher dosing, vertigo control was accompanied with the 
troubling symptoms of permanent, severe imbalance, and oscillopsia.
In 1957, Schuknecht [2] may have been the first to use intratympanic streptomy-
cin to alleviate vertigo attacks in patients with unilateral MD that was uncontrolled 
by traditional medical management. He conceived of this idea after noting that 
intratympanic formalin will readily pass into the inner ear and prevented post-
mortem degeneration of the inner ear membranous structures in patients. He 
correctly theorized that streptomycin could also pass into the inner ear and devised 
a cat animal model that demonstrated clinical and pathologic vestibulotoxicity with 
intratympanic streptomycin. Based on these results, he devised a clinical trial of 
intratympanic streptomycin administration to patients with uncontrolled unilateral 
MD. He administered variable amounts of streptomycin (between 0.125 and 0.5 g), 
either hourly or over 4 hours, over a variable amount of days. The first group of 
three patients who received 1 or 2 days of treatment achieved only brief control of 
their vertigo, but did not lose any hearing. Subsequently, an additional group of five 
patients received streptomycin for 3 days or longer. These patients had permanent 
resolution of their vertigo episodes, but at the cost of deafening the ear. Schuknekt 
coined the term “chemical labyrinthectomy” to describe this phenomenon. He 
concluded that intratympanic streptomycin at the therapeutic dosage failed to pre-
serve hearing, and should only be considered for patients who are not good surgical 
candidates, but would otherwise be proper candidates for inner ear ablation [2].
With the administration of intratympanic aminoglycosides, chemical ablation of 
the inner ear via systemic administration of aminoglycosides fell into disfavor due to 
the side effects of bilateral vestibulopathy, nephrotoxicity, and unpredictable results. 
However, choosing which kind of aminoglycoside for intratympanic injection has 
gradually changed. In 1977, Lange [3] appears to be the first to have used IT adminis-
tration of gentamicin. He reported about 55 patients suffering from severe unilateral 
MD, seen over a period of 3–10 years. Patients were treated with intratympanic 
administration of streptomycin or better, gentamicin. The medication was given 
using a plastic tube inserted behind the annulus within the transmeatal approach, 
and 0.1 ml gentamicin (earlier streptomycin) was instilled every 5 hours until the 
first signs of inner ear reaction (nystagmus or vertigo) appeared. In 90% of the 
cases, vertiginous attacks ceased after therapy, and hearing was preserved in 76%.
Entering the 1990s, intratympanic gentamicin had gained widespread popular-
ity in the treatment of MD. Compared with streptomycin, ITG for treatment of MD 
provided equivalently excellent vertigo control while showing a lower incidence of 
hearing loss in early clinical data. Gentamicin gained popularity over streptomycin 
and gradually came to be the drug of choice for chemical ablation of inner ear.
In 1993, Nedzelski et al. [5] studied 50 patients with unilateral MD by treatment 
of microcatheter administration of streptomycin over a 5 h treatment, 4 treatments 
within 48 hours, and the rate of vertigo control was up to 96%; only 24% of his 
patients experienced various degrees of hearing loss. Although streptomycin was 
being used in the study, he advocated for using gentamicin instead for its theoretical 
reduction of cochleotoxicity.
Beck and Schmidt [6] reported on their 10 years of experience with intratym-
panally applied streptomycin and gentamicin in the therapy of MD. They theorized 
that the dosage might be a critical factor for hearing preservation with vertigo 
control. Aminoglycosides could be titrated to impede the secretory epithelium 
of the vestibular apparatus without destroying the sensory cells, thus achieving 
vertigo control while maintaining caloric response, that is, vestibulo-ocular reflex. 
More importantly, risk of deafness could potentially be eliminated. By reducing the 
dosage delivered and titrating, they were able to achieve excellent rates of vertigo 
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control (92%) while also achieving respectable hearing preservation rates (15% 
hearing loss with no cases of deafness).
During the same era, around the early 1990s, two schools of thought emerged 
in an effort to standardize ITG treatment, dubbed the “shotgun” approach, and 
the “low-dose” approach. The shotgun approach, championed by Nedzelski and 
others [5], was characterized by daily IT injections to a fixed endpoint or to a clini-
cal threshold that heralded damage to the inner ear. Proponents of this approach 
attempted to achieve adequate vestibular ablation for long-term vertigo control. The 
low-dose approach, championed by Magnusson and others [7], was characterized 
by weekly IT injections, also to a fixed endpoint or to clinical effect. Proponents of 
this approach tried to achieve vertigo control while minimizing damage to hearing 
and potentially preserving the caloric response as well.
Today, intratympanic injection of gentamicin is probably the most effective non-
surgical treatment to eradicate vertigo in MD. Yet, it is an ablative method that car-
ries a non-negligible risk of hearing loss. Currently, gentamicin is usually instilled 
via IT injection or through a tympanostomy tube to the round window niche. These 
injections are repeated over a variable amount of time, typically between daily to 
weekly injections, until a clinical endpoint is achieved or until there is a decline in 
hearing. No consensus has been reached so far on the overall dosage, dosing meth-
ods, timing of delivery, treatment duration, clinical endpoint of therapy, or con-
centration of gentamicin. Both clinical evidence and basic science models should be 
further studied to scientifically elicit the most effective and safe regimen.
3. Mechanism of action
Aminoglycoside antibiotics have a well-documented history of cochleotoxic and 
vestibulotoxic effects. Administration of intratympanic aminoglycoside antibiotics 
to patients with MD is based on the notion that the patient’s vestibular symptoms 
are due to the damaged and distorted vestibular signals emanating from their ear 
and that they are better off with no signal than with a damaged and distorted sig-
nal. The objective of ITG is to weaken vestibular signals in the Ménière’s ear to the 
point at which they are no longer strong enough to generate a vertigo attack. Ideally, 
aminoglycosides would act to reduce vestibular function, and thus alleviate the 
patient’s symptoms of vertigo, while preserving hearing. The degree to which a drug 
is cochleotoxic or vestibulotoxic differs among aminoglycosides. Gentamicin and 
streptomycin, for instance, are reported to be more vestibulotoxic. Other amino-
glycosides, such as amikacin, are considered to be relatively more cochleotoxic and 
thus are not used transtympanically. The best evidence for this is the simple clinical 
observation that patients undergoing systemic gentamicin or streptomycin therapy 
experience vestibulopathy much more commonly than hearing loss. This feature 
has been used by otologists to control the vestibular symptoms of MD, initially 
provided through systemic delivery by Fowler [1] and subsequently through IT 
injections by Schuknecht [2, 8]. Use of streptomycin has been largely replaced by 
gentamicin which is thought to be more selectively vestibulotoxic and better able 
to preserve residual hearing in patients with unilateral MD refractory to medical 
management [9, 10].
Within the bony labyrinth, several studies have investigated the trafficking and 
distribution of aminoglycosides, finding different patterns of distribution depen-
dent upon the dose, duration, and route of administration. IT-injected aminogly-
cosides appear to gain access to the inner ear via the oval window and the round 
window [11, 12], and uptake either by passive diffusion or by endocytosis [13, 14].  
Salt et al. recently quantified diffusion of gentamicin through the oval (35%) 
5Intratympanic Gentamicin Treatment for Ménière’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.86790
versus the round window (57%) [12, 15]. Access to these membranous structures is 
however uncertain, partly due to their variable permeability in individuals, result-
ing in unpredictable drug exposure of the inner ear [16–18]. Similar mechanisms 
of cellular trafficking (active diffusion and endocytosis) have been proposed in the 
transport of aminoglycosides into cells of the inner ear [19].
Once the drug crosses the oval window and the round window, the situation 
becomes more complex and the precise mechanism by which aminoglycosides exert 
their toxic effects on hair cells is unknown, to date. Previous animal studies showed 
that in the cochlea, sensory hair cells, the spiral ligament including the stria vascu-
laris, and spiral ganglion cells had a very early uptake of gentamicin. Similarly, hair 
cells, dark cells, and vestibular ganglion cells are the primary targets in the vestibu-
lar system. This may demonstrate that gentamicin most likely diffuses across the 
inner ear membranes, readily achieving concentrations within the scala vestibuli, 
cochlear duct, and vestibule and then exerts its cellular toxicity.
Multiple mechanisms, including disruption of calcium-dependent cytokine 
production resulting in the damage to hair cell membrane integrity, increased 
superoxide production, hair cell transduction blockage, glutamate decarboxylase 
inhibition, ornithine decarboxylase inhibition, and free radical damage, all have 
been developed to explain aminoglycosides’ direct toxicity to hair cells [10, 20, 21].  
While most cells of the inner ear demonstrate aminoglycoside penetration, several 
studies have identified preferential loss of the hair cells at the basal turn of the 
cochlea over the apical hair cells and vestibular type I hair cells over their type II 
counterparts [22–26]. Direct damage to the spiral ganglion has also been observed 
[27] and histologic studies in rhesus monkeys suggest relative sparing of the 
maculae [28].
In parallel to previous findings, several studies have demonstrated that direct 
application of gentamicin into the vestibular labyrinth also causes greater loss of 
type I versus type II vestibular hair cells [29, 30]. Recently, Lyford-Pike et al. [26] 
used the animal model, chinchilla, to provide the evidence that the selective loss 
of type I hair cells assuredly occurred because these cells preferentially accumulate 
gentamicin acutely after intratympanic administration. Type II hair cells and sup-
porting cells concentrate substantially less gentamicin. These results might theoreti-
cally ameliorate the more profound symptom of vertigo (driven by type I hair cells) 
while preserving cochlear function.
Aminoglycosides may also act to inhibit production of endolymph, restoring 
the balance between endolymphatic and perilymphatic pressure. This would also 
act to alleviate all symptoms of endolymphatic hydrops. Additionally, aminogly-
cosides are theorized to cause selective damage to the cells of the cochlear stria 
vascularis and planum semilunatum in the cristae ampullae of the semicircular 
canals, which are involved in ionic regulation and endolymph production [31]. It is 
also known that gentamicin utilizes the cellular machinery of endolymph produc-
tion to traffic into the inner ear after systemic administration [32]. The theory 
that vestibular dark cells and, thus, endolymphatic flow, are the targets by which 
aminoglycosides alleviate vertigo is of significant clinical interest because it sug-
gests that it is not necessarily important to ablate the vestibule to achieve vertigo 
control in MD. This idea can explain why patients with intact caloric responses 
can still achieve significant vertigo control after intratympanic aminoglycoside 
administration.
In conclusion, direct toxicity to vestibular hair cells and direct toxicity to the 
endolymph producing apparatus might be the two major mechanisms of action by 
ITG. Most importantly, gentamicin has been proved to be more vestibulotoxic than 
cochleotoxic in humans. The inner ear toxicity of gentamicin might follow an order. 
Secretory dark cells of the vestibule might be the first to be damaged, followed by 
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the vestibular neuroepithelium and the afferent vestibular fibers, and finally, the 
hair cells of the organ of Corti are destroyed [33, 34].
4. Therapeutic method and treatment efficacy
Ménière’s disease is manifested by episodic vertigo, tinnitus, aural fullness, and 
fluctuating hearing loss. The treatment of patients with MD is usually directed 
at the most disabling symptom, which is the debilitating vertigo. MD treatment 
protocols typically measure vertigo control according to AAO-HNS Committee on 
Hearing and Equilibrium guidelines for grading vertigo severity [35]. Often, clinical 
trials also attempt to assess other disease sequelae such as hearing loss, tinnitus, and 
aural fullness.
As a well-known relapsing-remitting disease, it is rather difficult to accurately 
evaluate the efficacy of ITG in treatment of MD. Firstly, the natural history of 
remission and exacerbation of symptoms make evaluation of the effectiveness of 
treatment remarkably difficult. Commonly, vertigo attacks can improve without 
treatment of any kind as periods of remission are not uncommon. Thus, a clinical 
trial without controls will not account for this finding. Another difficulty is that 
clinical researchers attempt to show hearing preservation with IT gentamicin pro-
tocol, but hearing tends to worsen over time in MD regardless of treatment. Finally, 
the variable nature of MD with fluctuation in levels of hearing and even frequency 
and severity of vertigo can make clinical trials difficult.
To date, there have only been a few interventional randomized controlled trials 
investigating the true efficacy of ITG in the treatment of MD. In 2004, the first 
prospective, double-blind, randomized clinical trial of intratympanic gentamicin 
versus intratympanic buffer solution (placebo) in patients with active MD was 
reported by Stokroos et al. [36]. They performed ITG injections with buffered 
gentamicin (30 mg/ml) every 6 weeks until the vertigo complaints disappeared (12 
patients received gentamicin versus 10 for placebo), outcome measures included 
the number of vertiginous spells, degree of sensorineural hearing loss, labyrinthine 
function, and labyrinthine asymmetry. Compared to the placebo group, topical 
gentamicin provided a significant improvement in the number of vertiginous 
attacks per year at follow up which varied between 6 and 28 months. There was 
no statistically significant change in hearing or other outcomes in two groups. 
However, hearing had a tendency to deteriorate in the placebo-treated patients, due 
to the natural course of the disease, which suggests that early treatment with topical 
gentamicin may preserve residual sensorineural hearing in active MD.
In 2008, Postema et al. [37] reported another prospective, double-blind, ran-
domized, placebo-controlled trial associated with ITG therapy for control of vertigo 
in unilateral MD. They used weekly injections of 0.4 ml of gentamicin (30 mg/ml). 
A total of 4 injections were given through a ventilation tube (16 patients received 
gentamicin and 12 received a placebo). The results showed that gentamicin treat-
ment resulted in a significant reduction of the score for vertigo complaints (includ-
ing vertigo severity) and the score for perceived aural fullness. They also noted that 
a small increase in hearing loss (average of losses at 0.5, 1, 2, and 4 kHz: 8 dB HL) 
was measured in the gentamicin group.
In 2016, Patel et al. [38] performed a randomized, double-blind, comparative 
effectiveness trial of intratympanic methylprednisolone (n = 30) versus gentamicin 
(n = 30) in patients with refractory unilateral MD. Patients were randomly assigned 
(1:1) to two intratympanic methylprednisolone (62.5 mg/ml) or gentamicin (40 mg/ml)  
injections given 2 weeks apart, and were followed up for 2 years. In the methylpred-
nisolone group, complete vertigo control (Class A) was achieved in 21/30 patients 
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(70%) compared to 25/30 (83.3%) in the gentamicin group. After methylpredniso-
lone, 22 patients (78.5%) experienced an improved functional level score and 8 
patients (28.7%) better pure-tone hearing and speech discrimination. There were also 
reductions for tinnitus, dizziness, and aural fullness. Fifteen patients (50%) required 
further courses of methylprednisolone. Two patients were deemed treatment fail-
ures and were assigned ITG treatment. The study showed no significant difference 
between the methylprednisolone and gentamicin for the control of vertigo, total 
number of injections, number of patients with relapsing vertigo, or the amount of 
pain from injection but better speech discrimination after methylprednisolone.
Based on the above prospective, double-blind, randomized controlled clinical 
trials, intratympanic gentamicin, as a medically ablative method, seems to be the 
most effective non-surgical treatment to eradicate vertigo in intractable MD, but 
with a potential risk of hearing loss. However, there is no consensus on the treat-
ment protocol of ITG, especially for the concentration of gentamicin, dosage in 
each application, number of injection, and the time interval between two doses.
In the over 40 years of clinical trials in the treatment of MD by ITG, the major-
ity are case series without controls, mainly because of the significant difficulties in 
conducting the randomized controlled clinical trials or case/control trials [33]. In 
earlier studies, the highest rate of vertigo control was reported with daily injections 
or multiple titrations. On the other hand, considerable hearing loss was experienced 
in several studies. Moller et al. [39] treated 15 patients with disabling MD with daily 
injections for periods ranging from 3 to 11 days. They achieved 93.4% of vertigo 
control, but also 33.4% of hearing loss. They reported that none of the patients were 
responsive to caloric stimulation. Laitakari [40] reported 90% of vertigo control 
and 45% of hearing loss in 20 patients who had daily ITG for a minimum of 3 con-
secutive days. Parnes and Riddell [41] reported 41.7% worsening of the hearing in 
their group of patients who received three daily injections within 4 days. Murofushi 
et al. [42], using several daily injections, reported hearing loss in 30% of cases. 
Corsten et al. [43] reported 81% vertigo control but 57% hearing loss in patients 
(n = 21) who had gentamicin instillation 3 times a day for 4 consecutive days. 
Kaplan et al. [44] reviewed the 10-year long-term results of 114 patients treated 
with gentamicin instillation 3 times a day for 4 consecutive days. They achieved 
93.4% of vertigo control and 25.6% of hearing loss.
In the early 2000s, regarding patients with hearing deterioration and even 
those becoming deaf, there was a discussion about reducing the gentamicin dose 
or performing the application at longer intervals. Daily titration methods were 
abandoned. Transtympanic gentamicin therapy was modified to weekly or monthly 
intervals as “needed” or “on demand” to reduce the symptoms of MD, aiming to 
maintain cochlear as well as vestibular function. Harner et al. [45] reported a very 
high rate of vertigo control with preservation of hearing in 43 patients. There 
were no patients with changes in cochlear function and ablation of the labyrinth. 
All patients received one injection, and half of them received a repeat injection 
1 month after therapy. Minor [46] used gentamicin on weekly intervals until the 
development of spontaneous nystagmus, head-shaking nystagmus, or head thrust 
sign. Vertigo was controlled in 91% of the patients, and profound hearing loss only 
occurred in 1 patient. Atlas and Parnes [47] reviewed the outcomes of 83 patients 
who received weekly injections. They reported hearing loss in 17% of the patients, 
with vertigo control in 84%. Martin and Perez [48] reported vertigo control in 
83.1% of the patients and hearing loss in 15.5% of them after gentamicin at weekly 
intervals. De Beer et al. [49] reported 15.8% with hearing loss and 80.7% with 
vertigo control after, between 1 and 10, intratympanic injections at a minimum 
interval of 27 days. Casani et al. [50] reported 12% hearing loss after a maximum of 
2 injections of gentamicin and 81% vertigo control.
Meniere’s Disease
8
Most recently, Vlastarakos et al. [51] published a systematic review looking at 
sustained-release delivery of IT gentamicin (dynamic-release versus sustained-
release vehicles). Dynamic release (microcatheter at the round window) was 
found to provide satisfactory vertigo control in 89.3% (70.9% reporting complete 
control). Sustained-release preparations (gentamicin-soaked wick/pledget) 
provided 82.2% satisfactory control in the pool of patients (75% with complete 
control). In patients receiving sustained-release preparations, complete hearing 
loss was reported in 31.1% patients with another 23.3% of patients experienc-
ing partial hearing loss. This adverse change in hearing was unacceptably high, 
reinforcing the suggestion of using a sustained-release vehicle only in patients 
who had failed IT gentamicin injections previously or those without serviceable 
hearing.
Commonly, intratympanic injection under otoscope or microscope is a simple 
and recommendable technique. The desired amount of gentamicin is injected over 
the round window through the posterosuperior quadrant of the tympanic mem-
brane. There are two common doses of gentamicin for injection. The standard 
intravenous preparation of gentamicin is 40 mg/ml, which can be buffered with 
8.4% sodium bicarbonate so that discomfort on injection is reduced. A total of 
1.5 ml of gentamicin mixed with 0.5 ml of sodium bicarbonate at these concentra-
tions will produce a final concentration of 26.6 mg/ml gentamicin. Approximately 
0.3–0.5 ml of solution is usually adequate to bathe the round window in solution. 
Typically, patients will remain lying flat with the injected ear up for 10 min to 1 
h. This procedure is generally well tolerated by patients, who should be told to 
expect brief pain on injection, followed by possible vertigo or disequilibrium. 
Warming the medication can help in this regard (preventing a cold caloric 
response).
Based on the combination of current clinical practice, basic science models, 
and results from clinical trials, low drug dose and long interval between injections, 
mainly in order to reduce the risk of deafness, are reasonably encouraged. The low 
dose method involves using 1–2 injections of gentamicin and waiting a month or 2 
weeks between injections. The rate of vertigo control may be up to 80–90%, with no 
significant side effects. The second injection is given only if there has been a vertigo 
spell 2 weeks prior. In other words, instead of titrating to the onset of damage to the 
vestibular system, the criterion is a positive effect on the disease. Occasionally, a 
third dose is given.
In short, whatever technique is used, the goal is to apply gentamicin to the round 
window in sufficient concentration and over a sufficient amount of time that it 
achieves a therapeutic effect while avoiding both local and systemic side effects, 
especially hearing loss.
5. Indications and contraindications
Not all patients with MD can be treated with ITG. Based on the international 
consensus on treatment of MD obtained from the IFOS meeting 2017 [52], 
MD should be treated with a step-by-step therapy. The first line of treatment 
includes the medical conservative treatment, such as dietary modification and 
oral medicine. After this line of treatment, 80% of patients with MD are cured 
or in remission. When the vertigo of MD fails to be controlled by the first-line 
treatment for more than 6 months, it will be regarded as intractable MD. Then 
the second line is the IT injections, mainly IT steroids as a conservative treat-
ment and ITG in the case of IT steroid failure, and preferentially in patients 
with hearing impairment. After the second line treatment, 90–95% of the total 
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patients are cured or in remission. The third line is the surgical, either conserva-
tive or destructive, treatment. For unilateral intractable MD with serviceable 
hearing (i.e., speech reception threshold better than 50 dB HL and speech dis-
crimination score of more than 50%) in the treated ear, treatment protocol with 
an injection repetition not shorter than 1 week between adjacent injections or 
one with injections on a monthly basis as “needed” is preferred. These methods 
provide the same level of vertigo control yet offer better preservation of hearing 
functions [33].
The best indication for ITG treatment appears to be the control of vertigo in 
profound hearing loss or non-serviceable ears, in which speech reception thresh-
old is worse than 50 dB HL and speech discrimination score less than 50% [53, 
54]. Under these scenarios, there is no need to consider the risk of deafness, and 
titration methods or multiple injections on a daily basis are preferred, since these 
methods have significantly elevated incidence of hearing loss [33]. Transmastoid 
labyrinthectomy has traditionally been offered for non-serviceable ears in patients 
with MD. This method has been the gold standard, and it is very effective in 
eradication of vertigo in more than 94% of patients. In comparison, ITG therapy 
provides a minimally invasive ambulatory substitute with low morbidity and 
fewer side-effects, which is also very cost effective to manage vertigo in these MD 
patients with non-serviceable ears [53].
Another important indicator is the control of vertigo in patients who have failed 
endolymphatic sac surgery. Marzo and Leonetti [55] have shown the effectiveness 
of ITG therapy for patients who have failed endolymphatic sac surgery, thus reduc-
ing the need for vestibular neurectomy in those with intractable disease.
To be allergic and hypersensitive to aminoglycosides are two absolute contra-
indications for ITG. It is worth noting that patients who carried the mitochondrial 
mutation of the gene MT-RNR1 (mitochondrially encoded 12S ribosomal RNA) 
are hypersensitive to aminoglycosides. A single injection of aminoglycosides 
results in complete and definitive deafness in subjects with this mutation [56]. A 
systematic genetic screening of MD patients is highly recommended to prevent 
the occurrence of bilateral deafness. The treatment is intended for the abolition 
of vestibular function; thus, administration of gentamicin must be done carefully 
in the elderly, who have difficulty attaining vestibular compensation, in patients 
with complications, or in those with bilateral MD. Taking also into consideration 
the fact that individual’s drug sensitivity depends on their genetic background, 
investigation of appropriate drug levels according to evidence-based medicine 
remains a future task.
6. Complications
The complications of ITG treatment are primarily bi-fold: one is the risk 
caused by drug toxicity of gentamicin, the other is the risk caused by intratym-
panic injection. Undoubtedly, the main risk of ITG treatment for vertigo is the 
sensorineural hearing loss and associated prolonged disequilibrium and ataxia, 
which are common complaints after this treatment. Less common side effects 
include local hemorrhage, allergic response and tympanic membrane perfora-
tion (especially in an irradiated or otherwise damaged tympanic membrane), 
local discomfort, inflammation, otitis media or externa, and transient vertigo 
caused by a caloric reflex effect from the instilled fluid [38, 57]. It is also criti-
cal to educate all patients who are given intratympanic aminoglycosides that 
bilateral permanent hearing loss is possible, even from one single unilateral 
injection.
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7. Conclusions
Intratympanic injection of gentamicin is probably the most effective non-
surgical treatment to eradicate vertigo in MD. But it is also an ablative method that 
carries a non-negligible risk of hearing loss. Gentamicin has been proved to be more 
vestibulotoxic than cochleotoxic; direct toxicity to vestibular hair cells and direct 
toxicity to the endolymph producing apparatus might be the two major mechanisms 
of action. To date, no consensus has been reached on the dosage, dosing methods, 
timing of delivery, treatment duration, clinical endpoint of therapy, and con-
centration of gentamicin. However, based on the combination of current clinical 
practice, basic science models, and results from clinical trials, low drug dose and 
long intervals between injections are reasonably recommended. The application of 
gentamicin-induced vestibular ablation has minimized the number of more invasive 
procedures such as unilateral labyrinthectomy and vestibular neurectomy. In com-
parison with surgery, the vertigo control is comparable, the overall cost is reduced, 
and complications are limited. ITG in treating intractable MD has gradually become 
a prevalent therapy during the past decades. However, to administer ITG treatment, 
multiple factors should be comprehensively considered including patient selection, 
pharmacological mechanism, drug dose, the interval of administration, complica-
tions, indications, and contraindications.
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